Clinical trial

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

NCT00526617

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention ABT-888 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Temozolomide Normalized identity: temozolomideView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-08-01

PhasePHASE1

Conditions

Non-hematologic Malignanciesunresolved

Metastatic Melanomaverified · MONDO: metastatic melanoma

Breast Cancerverified · MONDO: breast cancer

Ovarian Cancerverified · MONDO: ovarian cancer

Primary Peritoneal Cancerverified · MONDO: primary peritoneal carcinoma

Fallopian Tube Cancerverified · MONDO: fallopian tube cancer

Hepatocellular Carcinomaverified · MONDO: hepatocellular carcinoma

Interventions

ABT-888DRUG

TemozolomideDRUG · verified · RxNorm: temozolomide

Sponsors & collaborators

AbbVielead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00526617 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.